Candel Therapeutics (CADL) Assets Average (2021 - 2025)

Candel Therapeutics' Assets Average history runs 5 years deep, the most recent figure standing at $109.4 million for Q4 2025.

• In Q4 2025, Assets Average rose 70.42% year-over-year to $109.4 million; the TTM figure through Dec 2025 stood at $109.4 million (up 70.42% YoY), while the FY2025 annual figure was $116.0 million, up 56.73% from the prior year.
• Assets Average came in at $109.4 million for Q4 2025 at Candel Therapeutics, up from $99.8 million in the prior quarter.
• In the past five years, Assets Average ranged from a high of $109.4 million in Q4 2025 to a low of $24.0 million in Q3 2024.
• A 5-year average of $73.3 million and a median of $76.9 million in 2022 frame the typical range for Assets Average.
• Across the five-year window, Assets Average sank 55.87% in 2024 and surged 315.75% in 2025, its largest moves.
• Candel Therapeutics' Assets Average stood at $92.6 million in 2021, then declined by 12.13% to $81.3 million in 2022, then plunged by 43.91% to $45.6 million in 2023, then surged by 40.68% to $64.2 million in 2024, then jumped by 70.42% to $109.4 million in 2025.
• According to Business Quant data, Assets Average over the past three periods registered $109.4 million, $99.8 million, and $100.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.

Peer Comparison